Skip to content
Research/Hormone Optimization/Testosterone Propionate

Testosterone Propionate

Short-acting testosterone ester (half-life ~1-3 days). More frequent dosing required. Allows rapid adjustment. IM/SubQ injection.

Intelligence Profile

Research Papers

Research Papers and Clinical Trials

Current research on testosterone propionate spans several therapeutic areas, though the available evidence is limited and comes primarily from preclinical studies and small clinical investigations.

Preclinical Research

Most published research focuses on testosterone's broader effects rather than testosterone propionate specifically. Recent animal studies have explored testosterone's role in pain perception and empathetic behaviors in mice, though the clinical relevance remains unclear. Other preclinical work has examined testosterone dynamics in polycystic ovary syndrome (PCOS) models and benign prostatic hyperplasia, but these studies don't directly evaluate testosterone propionate as a therapeutic intervention.

One notable study developed silicone-based testosterone propionate implants for sustained hormone delivery in juvenile castrated male pigs, demonstrating the compound's potential for controlled-release formulations. However, this represents early-stage drug delivery research rather than efficacy data.

Clinical Trial Activity

Clinical trials investigating testosterone formulations show mixed progress. A Phase 3 study (NCT03242590) examining oral testosterone undecanoate has been completed, though results for testosterone propionate specifically are not detailed in available records. Another completed Phase 3 trial (NCT01816295) evaluated testosterone solution effects on hormone levels, libido, and energy in men with low testosterone.

Currently active research includes a Phase 4 trial (NCT04807894) investigating vaginal testosterone for preventing recurrent urinary tract infections, which is still recruiting participants. However, a Phase 1/2 study (NCT01122342) examining vaginal testosterone cream for atrophic vaginitis in breast cancer patients taking aromatase inhibitors has been suspended.

A Phase 2 trial (NCT00080756) combining deslorelin with low-dose testosterone and estradiol for breast cancer prevention in high-risk premenopausal women remains active but not recruiting new participants.

Evidence Limitations

The available evidence base for testosterone propionate is quite thin. Most studies focus on other testosterone formulations or examine testosterone's general physiological effects rather than specific clinical applications of testosterone propionate. Sample sizes, study designs, and outcome measures are not consistently reported across the available literature, making it difficult to draw definitive conclusions about efficacy and safety.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider for personalized treatment recommendations.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.